BIOPHYTIS(EPA:ALBPS) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, ALBPS scores 0 out of 10 in our fundamental rating. ALBPS was compared to 72 industry peers in the Biotechnology industry. Both the profitability and financial health of ALBPS have multiple concerns. ALBPS is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALBPS had negative earnings in the past year.

ALBPS had a negative operating cash flow in the past year.

ALBPS had negative earnings in each of the past 5 years.

In the past 5 years ALBPS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of ALBPS (-172.99%) is worse than 76.39% of its industry peers.

		Industry Rank	Sector Rank
ROA	-172.99%
ROE	N/A
ROIC	N/A

ROA(3y)-113.95%

ROA(5y)-107.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALBPS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALBPS has more shares outstanding

ALBPS has less shares outstanding than it did 5 years ago.

The debt/assets ratio for ALBPS is higher compared to a year ago.

2.2 Solvency

ALBPS has an Altman-Z score of -9.58. This is a bad value and indicates that ALBPS is not financially healthy and even has some risk of bankruptcy.

ALBPS's Altman-Z score of -9.58 is on the low side compared to the rest of the industry. ALBPS is outperformed by 75.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-9.58

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.41 indicates that ALBPS may have some problems paying its short term obligations.

ALBPS's Current ratio of 0.41 is on the low side compared to the rest of the industry. ALBPS is outperformed by 81.94% of its industry peers.

A Quick Ratio of 0.41 indicates that ALBPS may have some problems paying its short term obligations.

ALBPS has a worse Quick ratio (0.41) than 80.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.41
Quick Ratio	0.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALBPS have decreased strongly by -8080.37% in the last year.

EPS 1Y (TTM)-8080.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-8203%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALBPS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.18% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y65.17%

EPS Next 2Y20.1%

EPS Next 3Y26.18%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALBPS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALBPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALBPS's earnings are expected to grow with 26.18% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y20.1%

EPS Next 3Y26.18%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALBPS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOPHYTIS

EPA:ALBPS (3/7/2025, 7:00:00 PM)

0.3

+0 (+1.35%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-25 2024-09-25

Earnings (Next)04-07 2025-04-07/amc

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners0.28%

Ins Owner ChangeN/A

Market Cap3.44M

Analysts84.44

Price Target0.84 (180%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-62.9%

PT rev (3m)-62.9%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-1008.7%

EPS NY rev (3m)7.11%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-41.67%

Revenue NY rev (3m)16.67%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-6.54

EYN/A

EPS(NY)-3.45

Fwd EYN/A

FCF(TTM)-0.94

FCFYN/A

OCF(TTM)-0.93

OCFYN/A

SpS0

BVpS-0.56

TBVpS-0.78

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-172.99%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-113.95%

ROA(5y)-107.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	20.12%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.41
Quick Ratio	0.41
Altman-Z	-9.58

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)55.71%

Cap/Depr(5y)70.24%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-8080.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-8203%

EPS Next Y65.17%

EPS Next 2Y20.1%

EPS Next 3Y26.18%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y31.73%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year44.44%

EBIT Next 3Y33.33%

EBIT Next 5YN/A

FCF growth 1Y48.31%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y48.16%

OCF growth 3YN/A

OCF growth 5YN/A

BIOPHYTIS (ALBPS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens